Lifevantage Corp reported the three months ended March 31, 2026 results: revenue $43.7 million, net income $1.4 million, EPS $0.11 per diluted share. Guidance lowered.
“For the third quarter ended March 31, 2026, the Company reported revenue of $43.7 million, a 25.2% decrease compared to revenue of $58.4 million in the third quarter of fiscal 2025. Revenue in the Americas region for the third quarter of fiscal 2026 decreased 28.9% primarily due to declines in sales of the MindBody GLP-1 System Ò , partially offset by sales of LoveBiome, which the Company acquired in October 2025. Revenue in the Asia/Pacific & Europe region decreased 7.7%; on a constant currency basis, revenue in the Asia/Pacific & Europe region decreased approximately 8.9%. Gross profit for the third quarter of fiscal 2026 was $34.5 million, or 79.0% of revenue, compared to $47.3 million, or 81.0% of revenue, for the same period in fiscal 2025. The decrease in gross profit as a percentage of revenue was primarily due to an allowance for inventory obsolescence related to the MindBody GLP-1 System Ò , along with increases in shipping and warehouse related expenses. Adjusted for the allo”
Rajendran Anbalagan was appointed as Director at Lifevantage Corp.
“On August 26, 2024, the Board, based on the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Rajendran Anbalagan as a member of the Board, effective immediately.”
Erin Brockovich resigned as Director at Lifevantage Corp.
“On August 23, 2024, Erin Brockovich, a member of the Board of Directors (the “Board”) of LifeVantage Corporation (the “Company”), notified the Company of her resignation as a member of the Board and any committees of the Board, effective August 26, 2024.”
Earnings Releases
Lifevantage Corp reported three and nine months ended March 31, 2024 results: revenue $48.2 million, net income $1.7 million, EPS $0.13 per diluted share. Guidance lowered.
“health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2024. Third Quarter Fiscal 2024 Summary*: • Revenue of $48.2 million, a decrease of 10.2% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue was down approximately 8.7%; • Revenue in”
Debt Financings
Lifevantage Corp incurred revolving credit of $5,000,000 with Bank of America, N.A. at the greater of the Term SOFR Daily Floating Rate or 0.00%, plus 2.00% maturing April 12, 2027.
“The Loan Agreement provides for a revolving line of credit in aggregate principal amount not to exceed $5,000,000 (the "Line of Credit").”
Material Agreements
Lifevantage Corp entered into Loan Agreement with Bank of America, N.A. valued at $5,000,000 (effective 2024-04-12).
“On April 12, 2024, LifeVantage Corporation (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Bank of America, N.A., as Lender (the “Lender”).”
Material Agreements
Lifevantage Corp entered into Cooperation Agreement with the entities and persons listed on Exhibit A and Exhibit B (collectively, the Stockholder Parties) (effective 2024-02-14).
“LifeVantage Corporation (the “Company”) entered into a Cooperation Agreement (the “Agreement”) with the entities and persons listed on Exhibit A thereto (collectively, the “Radoff Parties”) and the entities and persons listed on Exhibit B thereto (collectively, the “Sudbury Parties,” and together with the Radoff Parties, the “Stockholder Parties”).”
Dayton Judd was appointed as Director at Lifevantage Corp.
“Effective as of February 14, 2024, Mr. Judd has been appointed as a member of the Board.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.